Incyte Corp Q2 2024 10-Q Filing
Ticker: INCY · Form: 10-Q · Filed: Jul 30, 2024 · CIK: 879169
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Incyte's 10-Q is out, showing Q2 and H1 2024 financials. Check product, royalty, and milestone revenues.
AI Summary
Incyte Corporation filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the year, detailing revenues from products, royalties, and milestone/contract revenues. Specific financial figures for these revenue streams and comparative periods are included in the filing.
Why It Matters
This filing provides investors with Incyte's latest financial performance and operational updates, crucial for understanding the company's current standing and future prospects in the biopharmaceutical sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Incyte faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-07-30 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Incyte Corp (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240730 (date) — Date of filing
FAQ
What were Incyte's total product revenues for the second quarter of 2024?
The filing indicates product revenues for the period April 1, 2024 to June 30, 2024, but the specific dollar amount is not detailed in this header information.
How do the first half 2024 revenues compare to the first half of 2023?
The filing covers the periods January 1, 2024 to June 30, 2024, and January 1, 2023 to June 30, 2023, allowing for comparison, though specific figures are not in the header.
What is Incyte Corporation's primary business classification?
Incyte Corporation is classified under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731].
When was Incyte Corporation incorporated?
Incyte Corporation was incorporated in Delaware (DE).
What is the fiscal year end for Incyte Corporation?
Incyte Corporation's fiscal year ends on December 31 (1231).
Filing Stats: 4,589 words · 18 min read · ~15 pages · Grade level 18.8 · Accepted 2024-07-30 16:10:17
Filing Documents
- incy-20240630.htm (10-Q) — 1572KB
- incytecorporationexhibit101.htm (EX-10.1) — 1501KB
- incy-6302024xex311.htm (EX-31.1) — 10KB
- incy-6302024xex312.htm (EX-31.2) — 10KB
- incy-6302024xex321.htm (EX-32.1) — 4KB
- incy-6302024xex322.htm (EX-32.2) — 4KB
- 0000879169-24-000149.txt ( ) — 9949KB
- incy-20240630.xsd (EX-101.SCH) — 64KB
- incy-20240630_cal.xml (EX-101.CAL) — 73KB
- incy-20240630_def.xml (EX-101.DEF) — 373KB
- incy-20240630_lab.xml (EX-101.LAB) — 744KB
- incy-20240630_pre.xml (EX-101.PRE) — 578KB
- incy-20240630_htm.xml (XML) — 1001KB
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION 3 Item 1.
Financial Statements
Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Income (Loss) 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 27
Forward-Looking Statements
Forward-Looking Statements 27 Summary Risk Factors 30 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 56 Item 4.
Controls and Procedures
Controls and Procedures 56
: OTHER INFORMATION
PART II: OTHER INFORMATION Item 1A.
Risk Factors
Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 84 Item 5. Other Information 84 Item 6. Exhibits 85
Signatures
Signatures 86 2 Table of Contents
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements INCYTE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except number of shares and par value) June 30, 2024 December 31, 2023* (unaudited) ASSETS Current assets: Cash and cash equivalents $ 987,293 $ 3,213,376 Marketable securities—available-for-sale (amortized cost $ 464,272 and $ 442,816 as of June 30, 2024 and December 31, 2023, respectively; allowance for credit losses $ 0 as of June 30, 2024 and December 31, 2023) 462,207 442,667 Short term equity investments 69,875 — Accounts receivable 739,050 743,557 Inventory 100,704 62,972 Prepaid expenses and other current assets 207,956 182,830 Total current assets 2,567,085 4,645,402 Restricted cash 1,631 1,845 Long term equity investments 29,668 187,716 Inventory 255,268 206,965 Property and equipment, net 762,009 751,513 Finance lease right-of-use assets, net 25,535 25,535 Other intangible assets, net 113,536 123,545 Goodwill 155,593 155,593 Deferred income tax asset 729,561 631,886 Other assets, net 21,917 52,107 Total assets $ 4,661,803 $ 6,782,107 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 148,174 $ 109,601 Accrued compensation 113,536 153,348 Accrued and other current liabilities 1,034,316 935,569 Finance lease liabilities 3,874 3,439 Acquisition-related contingent consideration 37,155 38,422 Total current liabilities 1,337,055 1,240,379 Acquisition-related contingent consideration 156,845 173,578 Finance lease liabilities 28,745 29,162 Other liabilities 142,099 149,151 Total liabilities 1,664,744 1,592,270 Commitments and contingencies (Note 16) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; none issued or outstanding — — Common stock, $ 0.001 par value; 400,000,000 shares authorized; 191,572,449 and 224,286,862 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 191 224 Additional paid-in capital 4,382,734 5,01